Lifeward Ltd.
LFWDNasdaqHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · L3 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.7M | $435,000 | $352,000 | $432,000 | $330,000 |
| Operating income | −$19.7M | −$29.3M | −$23.6M | −$19.1M | −$12.7M | −$12.0M |
| Net income | −$19.9M | −$28.9M | −$22.1M | −$19.6M | −$12.7M | −$13.0M |
| Total assets | $22.9M | $30.5M | $63.2M | $74.2M | $94.8M | $28.1M |
| Total liabilities | $14.5M | $11.6M | $16.7M | $6.1M | $5.4M | $6.3M |
| Equity | $8.4M | $18.8M | $46.5M | $68.2M | $89.4M | $21.8M |
| EPS (diluted) | $-17.16 | $-39.96 | $-31.13 | $-2.20 | $-0.27 | $-0.82 |
| Shares out. | 10.6M | 59.5M | 59.5M | 62.5M | 33.4M | 12.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1405.3%
- Net margin
- −1422.4%
- Return on equity
- −236.8%
- Return on assets
- −87.0%
- Return on capital (ROCE)
- −181.1%
- Liabilities / assets
- 63.3%
- Debt / equity
- 1.72×
- Book value / share
- $0.79
- Revenue growth (YoY)
- −17.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -44.62distress
- Accruals / assets
- −13.5%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2026
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Oramed Pharmaceuticals Inc.Activist (13D)May 14, 2026
- Intracoastal Capital, LlcPassive (13G)Jul 1, 2025
- Lind Global Fund Ii LpPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 133,618 | 18.6 | -4.3% |
| Apr 30, 2026 | 139,695 | 15.1 | -3.2% |
| Apr 15, 2026 | 144,267 | 23.5 | -8.2% |
| Mar 31, 2026 | 157,182 | 11.8 | -24.5% |
| Mar 13, 2026 | 208,221 | 13.3 | -8.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 19, 2026
- Results of operationsMay 15, 2026
- Director / officer changeApr 23, 2026
- Other material eventMar 31, 2026
- Completed an acquisition or disposition · Unregistered equity sale · Director / officer changeMar 25, 2026
- Delisting / listing-standard noticeMar 20, 2026
- Results of operationsMar 18, 2026
- Shareholder voteMar 13, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.